← Back to Skills Marketplace

Biomarin

Name: Biomarin
Author: hanxueyuan

by hanxueyuan · GitHub ↗ · v1.0.0 · MIT-0

cross-platform ✓ Security Clean

Downloads

Stars

Active Installs

Versions

Install in OpenClaw

/install biomarin

Description

BioMarin specializes in rare genetic metabolic diseases with enzyme replacement and gene therapies, holding multiple orphan drug approvals globally.

README (SKILL.md)

BioMarin Pharmaceutical

发展历程

1997: 在加州成立，创始团队来自UCSF和Genentech
1999: 纳斯达克上市，代码BMRN
2000s: 专注酶替代疗法(ERT)，开发Naglazyme和Aldurazyme
2014: Kynamro获批，进入罕见代谢疾病核心市场
2017: Voxzogo(软骨发育不全)进入临床试验，成为关键管线
2020: Roctavian(血友病A基因疗法)提交上市申请，进入基因治疗领域
2021: Voxzogo获FDA批准，年峰值销售预期超$10亿
2023: 年营收突破$25亿，首次实现全年盈利
2024: 与多家大型药企探讨收购，估值超$150亿

核心业务

酶替代疗法(核心收入来源) + 小分子药物 + 基因疗法(新兴管线)，主要面向全球罕见病患者群体

竞争优势

20+年罕见病临床数据积累、FDA孤儿药独占期保护、全球罕见病诊疗网络合作关系、极高转换成本的终身治疗方案

关键指标

2023年营收$25亿+；8款上市药物；全球超25个获批市场；研发投入占收入30%+

故事

罕见病药物定价逻辑独特——BioMarin的某些药物年治疗费用超过$30万美元，但因为患者总数极少(某些疾病全球仅数千例)，整体市场规模与传统药物不同，定价策略基于'节省的终身护理成本'而非'研发成本分摊'

Usage Guidance

This skill appears safe from a security perspective. Treat its business and pharmaceutical claims as informational content from an unknown source, and verify important facts independently before relying on them.

Capability Analysis

Type: OpenClaw Skill Name: biomarin Version: 1.0.0 The skill bundle contains purely informational content about BioMarin Pharmaceutical, including its history, core business, and market metrics. There is no executable code, network activity, or malicious prompt injection instructions in SKILL.md or _meta.json.

Capability Assessment

✓ Purpose & Capability

The skill content is a static company overview focused on BioMarin's history, business model, therapies, and market position.

✓ Instruction Scope

The instructions only describe when the agent should read the information; they do not redirect user goals, require hidden actions, or request autonomous operations.

✓ Install Mechanism

There is no install spec and no code files; the provided artifact is a single SKILL.md document.

✓ Credentials

The skill requests no binaries, environment variables, credentials, config paths, filesystem access, or network access.

✓ Persistence & Privilege

No persistence, background execution, privileged access, or account authority is described in the artifacts.

How to Use

Make sure OpenClaw is installed (local or Docker)
Run the install command in chat: /install biomarin
After installation, invoke the skill by name or use /biomarin
Provide required inputs per the skill's parameter spec and get structured output

Version History

v1.0.0

BioMarin Pharmaceutical 1.0.0 — 初始版本发布 - 简要介绍公司历史和里程碑，包括成立、上市、核心产品批准及最新财务表现 - 概述核心业务结构：酶替代疗法、小分子药物、基因治疗 - 总结公司在罕见病领域的竞争优势 - 量化关键指标，如营收、上市药物数量和研发投入比例 - 补充罕见病药物定价与业务模式说明，强化行业理解

Metadata

Slug biomarin

Version 1.0.0

License MIT-0

All-time Installs 0

Active Installs 0

Total Versions 1

Frequently Asked Questions

What is Biomarin?

BioMarin specializes in rare genetic metabolic diseases with enzyme replacement and gene therapies, holding multiple orphan drug approvals globally. It is an AI Agent Skill for Claude Code / OpenClaw, with 29 downloads so far.

How do I install Biomarin?

Run "/install biomarin" in the OpenClaw or Claude Code chat to install it in one step — no extra setup required.

Is Biomarin free?

Yes, Biomarin is completely free, licensed under MIT-0. You can download, install and use it at no cost.

Which platforms does Biomarin support?

Biomarin is cross-platform and runs anywhere OpenClaw / Claude Code is available (cross-platform).

Who created Biomarin?

It is built and maintained by hanxueyuan (@hanxueyuan); the current version is v1.0.0.

More Skills